C. Denton, N. Goh, S. Humphries, D. Lynch, T. Maher, R. Spiera, A. Devaraj, L. Ho, C. Stock, E. Erhardt, M. Alves, A. Wells, on behalf of the SENSCIS trial investigators
{"title":"SENSCIS试验中纤维化间质性肺病(ILD)的范围与基线时强迫肺活量(FVC)的关系以及系统性硬化症相关ILD (SSc-ILD)患者FVC的变化","authors":"C. Denton, N. Goh, S. Humphries, D. Lynch, T. Maher, R. Spiera, A. Devaraj, L. Ho, C. Stock, E. Erhardt, M. Alves, A. Wells, on behalf of the SENSCIS trial investigators","doi":"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1803","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":127613,"journal":{"name":"TP24. TP024 UNDERSTANDING AND TREATING AUTOIMMUNE LUNG DISEASE","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Associations Between Extent of Fibrotic Interstitial Lung Disease (ILD) and Forced Vital Capacity (FVC) at Baseline and Change in FVC in Subjects with Systemic Sclerosis-Associated ILD (SSc-ILD) in the SENSCIS Trial\",\"authors\":\"C. Denton, N. Goh, S. Humphries, D. Lynch, T. Maher, R. Spiera, A. Devaraj, L. Ho, C. Stock, E. Erhardt, M. Alves, A. Wells, on behalf of the SENSCIS trial investigators\",\"doi\":\"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1803\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":127613,\"journal\":{\"name\":\"TP24. TP024 UNDERSTANDING AND TREATING AUTOIMMUNE LUNG DISEASE\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TP24. TP024 UNDERSTANDING AND TREATING AUTOIMMUNE LUNG DISEASE\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1803\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP24. TP024 UNDERSTANDING AND TREATING AUTOIMMUNE LUNG DISEASE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Associations Between Extent of Fibrotic Interstitial Lung Disease (ILD) and Forced Vital Capacity (FVC) at Baseline and Change in FVC in Subjects with Systemic Sclerosis-Associated ILD (SSc-ILD) in the SENSCIS Trial